AU2016290523B2 - Fusion proteins which bind to human Fc receptors - Google Patents

Fusion proteins which bind to human Fc receptors Download PDF

Info

Publication number
AU2016290523B2
AU2016290523B2 AU2016290523A AU2016290523A AU2016290523B2 AU 2016290523 B2 AU2016290523 B2 AU 2016290523B2 AU 2016290523 A AU2016290523 A AU 2016290523A AU 2016290523 A AU2016290523 A AU 2016290523A AU 2016290523 B2 AU2016290523 B2 AU 2016290523B2
Authority
AU
Australia
Prior art keywords
seq
tailpiece
region
nos
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016290523A
Other languages
English (en)
Other versions
AU2016290523A1 (en
Inventor
Robert Anthony Griffin
David Paul Humphreys
Shirley Jane Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of AU2016290523A1 publication Critical patent/AU2016290523A1/en
Assigned to UCB Biopharma SRL reassignment UCB Biopharma SRL Amend patent request/document other than specification (104) Assignors: UCB BIOPHARMA SPRL
Application granted granted Critical
Publication of AU2016290523B2 publication Critical patent/AU2016290523B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016290523A 2015-07-06 2016-07-06 Fusion proteins which bind to human Fc receptors Ceased AU2016290523B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1511787.2 2015-07-06
GBGB1511787.2A GB201511787D0 (en) 2015-07-06 2015-07-06 Proteins
PCT/EP2016/065914 WO2017005767A1 (en) 2015-07-06 2016-07-06 Fusion proteins which bind to human fc receptors

Publications (2)

Publication Number Publication Date
AU2016290523A1 AU2016290523A1 (en) 2018-01-18
AU2016290523B2 true AU2016290523B2 (en) 2022-08-25

Family

ID=54013529

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016290523A Ceased AU2016290523B2 (en) 2015-07-06 2016-07-06 Fusion proteins which bind to human Fc receptors

Country Status (10)

Country Link
US (1) US20180194856A1 (enExample)
EP (1) EP3319991A1 (enExample)
JP (1) JP7097293B2 (enExample)
CN (1) CN108473571B (enExample)
AU (1) AU2016290523B2 (enExample)
BR (1) BR112017028331A2 (enExample)
CA (1) CA2991363A1 (enExample)
EA (1) EA201890225A1 (enExample)
GB (1) GB201511787D0 (enExample)
WO (1) WO2017005767A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016139006A (ru) 2014-03-05 2018-04-05 Юсб Биофарма Спрл Мультимерные fc-белки
SI3325011T1 (sl) 2015-07-24 2021-02-26 Gliknik Inc. Fuzijski proteini humanih proteinskih fragmentov za tvorbo pravilnih multimeriziranih imunoglobulin FC sestavkov s povečanim vezanjem komplementa
GB201607979D0 (en) * 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
SG11201900427PA (en) 2016-07-22 2019-02-27 Gliknik Inc Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding
IL266988B2 (en) 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds
JP7351835B2 (ja) * 2017-12-14 2023-09-27 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
EP3765492A1 (en) * 2018-03-16 2021-01-20 Liverpool School of Tropical Medicine Chimeric fc receptor binding proteins and uses thereof
CN115724985A (zh) * 2021-08-27 2023-03-03 三生国健药业（上海）股份有限公司 一种cdc平台抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011073692A1 (en) * 2009-12-18 2011-06-23 The University Of Nottingham Proteins, nucleic acid molecules and compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147326A1 (en) * 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US6475749B1 (en) * 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
DE10001372A1 (de) * 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
AU2012392760C1 (en) * 2012-10-17 2021-08-12 CSL Behring Lengnau AG Immunomodulatory proteins
EP3114137A1 (en) * 2014-03-05 2017-01-11 UCB Biopharma SPRL Multimeric fc proteins
RU2016139006A (ru) * 2014-03-05 2018-04-05 Юсб Биофарма Спрл Мультимерные fc-белки
WO2016139365A1 (en) * 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011073692A1 (en) * 2009-12-18 2011-06-23 The University Of Nottingham Proteins, nucleic acid molecules and compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTINA BRUNKE ET AL, MABS, US, (2013-11-01), vol. 5, no. 6, doi:10.4161/mabs.26396, ISSN 1942-0862, pages 936 - 945 *
Davis et al; "Intermolecular disulfide bonding in IgM: effects of replacing cysteine residues in the µ heavy chain"; The EMBO Journal (1989), vol.8, no.9, pp.2519-2526, *
SITIA R ET AL, "Developmental regulation of IgM secretion: The role of the carboxy-terminal cysteine", CELL, CELL PRESS, US, vol. 60, no. 5, doi:10.1016/0092-8674(90)90092-S, ISSN 0092-8674, (1990-03-09), pages 781 - 790, (1990-03-09) *

Also Published As

Publication number Publication date
CA2991363A1 (en) 2017-01-12
WO2017005767A1 (en) 2017-01-12
GB201511787D0 (en) 2015-08-19
CN108473571A (zh) 2018-08-31
EP3319991A1 (en) 2018-05-16
BR112017028331A2 (pt) 2018-09-11
US20180194856A1 (en) 2018-07-12
AU2016290523A1 (en) 2018-01-18
CN108473571B (zh) 2022-04-15
EA201890225A1 (ru) 2018-06-29
JP7097293B2 (ja) 2022-07-07
JP2018519834A (ja) 2018-07-26

Similar Documents

Publication Publication Date Title
US20180194856A1 (en) Fusion proteins which bind to human fc receptors
AU2015226100B2 (en) Multimeric Fc proteins
AU2015226101B2 (en) Multimeric Fc proteins
US20230241168A1 (en) April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
US20170029505A1 (en) Multimeric fc proteins
CN115916827A (zh) 免疫活化Fc结构域结合分子
US20180094059A1 (en) Single-chain tnf ligand family molecules and fusion proteins and derivatives thereof
CA2978501A1 (en) Polymeric fc proteins and methods of screening to alter their functional characteristics
WO2017036905A1 (en) Multimeric proteins which bind to human fc-receptors
JP2025535041A (ja) 自己抗体介在疾患の治療における使用のための変異ｔａｃｉ－ｆｃ融合タンパク質
WO2024046301A1 (zh) 包含taci多肽的融合蛋白及其用途
EP4519298A1 (en) Novel cd200 fusion proteins
CN114053403A (zh) 融合蛋白在制备疫苗佐剂或预防和治疗病毒感染的药物中的用途
CN114401985A (zh) 用于治疗免疫复合物介导的肾病症的重组IgG Fc多聚体

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: UCB BIOPHARMA SRL

Free format text: FORMER NAME(S): UCB BIOPHARMA SPRL

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired